CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is often driven by KRAS mutations, but inhibitors targeting the most frequent KRAS substitutions in PDAC are not yet approved in the clinic. We previously discovered that KRAS-mutant PDAC is sensitive to the combination of SHP2 and ERK inhi...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Antonio Mulero-Sánchez, Astrid Bosma, Bonifiya Visuvasam, Niki Pouliopoulou, Marieke van de Ven, Natalie Proost, Manon Boeije, Cor Lieftink, Roderick Beijersbergen, Rene Bernards, Sara Mainardi
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2026-01-01
Sarja:	Journal of Experimental & Clinical Cancer Research
Aiheet:	Targeted therapy Resistance K-RAS SHP2 ERK JUN
Linkit:	https://doi.org/10.1186/s13046-025-03616-z
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!